Trial Profile
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Lenalidomide (Primary)
- Indications Adenocarcinoma; Bladder cancer; Carcinoma; Mesothelioma; Neuroendocrine carcinoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Pelvic cancer; Penile cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions
- 13 Jul 2018 Status changed from active, no longer recruiting to completed.
- 07 Aug 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.
- 06 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.